Edition:
United States

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Global Market

1.49USD
14 Dec 2017
Change (% chg)

$-0.01 (-0.67%)
Prev Close
$1.50
Open
$1.50
Day's High
$1.50
Day's Low
$1.44
Volume
38,537
Avg. Vol
68,051
52-wk High
$16.96
52-wk Low
$1.21

Chart for

About

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $20.64
Shares Outstanding(Mil.): 13.85
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 190.77 15.47
EPS (TTM): -- -- --
ROI: -- -11.61 33.71
ROE: -- -35.87 16.38

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA

Dec 11 2017

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

Nov 13 2017

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

Nov 06 2017

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

Nov 03 2017

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

Oct 24 2017

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

Sep 07 2017

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

Aug 28 2017

BRIEF-Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

* Anthera Pharmaceuticals announces result phase 3 clinical study of Sollpura will be included in the European cystic fibrosis clinical trial network

Aug 14 2017

BRIEF-FDA grants orphan status to Anthera's kidney disease drug

* Anthera announces FDA orphan drug designation for blisibimod for the treatment of iga nephropathy

Aug 09 2017

BRIEF-Anthera Pharmaceuticals reports Q2 earnings per share $0.03

* Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results

Aug 09 2017

Earnings vs. Estimates